Peritransplant Use of Ultraviolet-B Irradiation (UV-B) Therapy Is Detrimental to Allogeneic Stem Cell Transplantation Outcome

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 6, 2006, Pages 665-671

  Yüksel, Meltem ^a   Baron, Elma ^a   Camouse, Melissa ^a   Cooper, Brenda W ^a   Lazarus, Hillard M ^a   Gerson, Stanton L ^a   Laughlin, Mary J ^a   Cooper, Kevin D ^a   Gilliam, Anita ^a   Fu, Pingfu ^a   Stevens, Seth ^b   Koç, Omer N ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Allogeneic stem cell transplantation; Graft versus host disease; UV B

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; FLUCONAZOLE; FLUDARABINE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; T6 ANTIGEN; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW CELL; BRONCHIOLITIS OBLITERANS; CANDIDIASIS; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR; DRUG FATALITY; FEASIBILITY STUDY; FEMALE; FUNGEMIA; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; LIVER DISEASE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG TOXICITY; MALE; MORTALITY; MUCORMYCOSIS; NEPHROTOXICITY; PERIPHERAL BLOOD STEM CELL; PHOTOTHERAPY; PNEUMOCYSTOSIS; RADIATION DOSE; SEPSIS; SKIN DISEASE; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; WHOLE BODY RADIATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD1; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PHOTOTHERAPY; SKIN; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; ULTRAVIOLET RAYS; WHOLE-BODY IRRADIATION;

EID: 33646768195     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.02.004     Document Type: Article

References (26)

1. Ringden O. Introduction to graft-versus-host disease. Biol Blood Marrow Transplant 11 suppl 2 (2005) 17-20
2. Armitage J. Bone marrow transplantation. N Engl J Med 330 (1994) 827-838
3. Tabbara I., Zimmerman K., Morgan C., and Nahleh Z. Allogeneic hematopoietic stem cell transplantation. complications and results. Arch Intern Med 162 (2002) 1558-1566
4. Svennilson J. Novel approaches in GVHD therapy. Bone Marrow Transplant 35 suppl 1 (2005) S65-S67
5. Roelandts R. The history of photochemotherapy. Photodermatol Photoimmunol Photomed 8 (1991) 184-189
6. Selgrade M., Smith M., Oberhelman-Bragg L., et al. Dose response for UV-induced immune suppression in people of color. differences based on erythemal reactivity rather than skin pigmentation. Photochem Photobiol 74 (2001) 88-95
7. Apisarnthanarax N., Donato M., Korbling M., et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation. feasibility and results. Bone Marrow Transplant 31 (2003) 459-465
8. Hudson J., Pamphilon D., Pullens R., et al. A comparison of four ultraviolet sources to alter graft-versus-host responses. Phys Med Biol 39 (1994) 1393-1406
9. McSweeney P., Niederwieser D., Shizuru J., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies. replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
10. Resnick I., Shapira M., and Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transpl Immunol 14 (2005) 207-219
11. Simon R. Optimal two-stage designs for phase II trials. Control Clin Trial 10 (1989) 1
12. Brown L., Cai T., and DasGupta A. Interval estimation for a binomial proportion. Stat Sci 16 (2001) 101-133
13. Oluwole S., Engelstad K., and James T. Prevention of graft-versus-host disease and bone marrow rejection. kinetics of induction of tolerance by UVB modulation of accessory cells and T cells in the bone marrow inoculum. Blood 81 (1993) 1658-1665
14. Azuma H., Ikebuchi K., Yamaguchi M., et al. Comparison of sensitivity to ultraviolet B irradiation between human lymphocytes and hematopoietic stem cells. Blood 96 (2000) 2632-2634
15. Cooper K., Oberhelman L., Hamilton T., et al. UV exposure reduces immunization rates and induces tolerance to epicutaneous antigens in humans. Relationship to dose, CD1a- DR+ epidermal macrophage induction and Langerhans cell depletion. Proc Natl Acad Sci USA 89 (1992) 8497-8501
16. del Rosario M., Zucali J., and Kao K. Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor. Blood 93 (1999) 3558-3564
17. Elmets C., Bergstresser P., Tigelaar R., et al. Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose ultraviolet radiation. J Exp Med 158 (1983) 781-794
18. Merad M., Hoffmann P., Ranheim E., et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 10 (2004) 510-517
19. Foss F., Gorgun G., and Miller K. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 29 (2002) 719-725
20. Truitt R., Johnson B., Hanke C., et al. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 163 (1999) 5145-5156
21. Elad S., Garfunkel A., Enk C., et al. Ultraviolet B irradiation. a new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88 (1999) 444-450
22. Baron E., Fourtanier A., Compan D., et al. High UVA protection affords greater immune protection confirming that UVA contributes to human immunosuppression. J Invest Dermatol 121 (2003) 869-875
23. Hammerberg C., Duraiswamy N., and Cooper K. Active induction of unresponsivenss (tolerance) to DNFB by in vivo UV-exposed epidermal cells is dependent upon infiltrating class II MHC+ CD11bbright monocytic/macrophagic cells. J Immunol 153 (1994) 4915-4924
24. Toichi E., McCormick T., and Cooper K. Cell surface and cytokine phenotypes of skin immunocompetent cells involved in ultraviolet-induced immunosuppression. Methods 28 (2002) 104-110
25. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 79 (2004) 209-215
26. Duffner U., Maeda Y., Cooke K., et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 172 (2004) 7393-7398